Inventiva Receives FDA Breakthrough Therapy Designation for Lead Drug Candidate Lanifibranor in NASH

Inventiva announced that the FDA has granted Breakthrough Therapy designation to lanifibranor, the company’s lead drug candidate, for the treatment of NASH.
[Inventiva]
Press Release
Bookmark

No account yet? Register

0
Share

Thyroid Hormones in Diabetes, Cancer, and Aging

Scientists describe the latest findings in thyroid hormone research in the field of aging, diabetes, and cancer, with a special focus on hepatocellular carcinomas.
[Aging Cell]
Gauthier, B. R., Sola‐García, A., Cáliz‐Molina, M. Á., Lorenzo, P. I., Cobo‐Vuilleumier, N., Capilla‐González, V., & Martin‐Montalvo, A. (n.d.). Thyroid hormones in diabetes, cancer, and aging. Aging Cell, n/a(n/a), e13260. https://doi.org/10.1111/acel.13260 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Shrimp Shells Extracted Chitin in Silver Nanoparticle Synthesis: Expanding Its Prophecy towards Anticancer Activity in Human Hepatocellular Carcinoma HepG2 Cells

The well-organized, simplistic, and biological route of AgNPs (AgNPs) was synthesized using shrimp shell extracted chitin as reducing, capping and stabilizing factor under the optimized conditions. The anticancer potential of synthesized biogenic AgNPs was evaluated against human hepatocarcinoma cells.
[International Journal of Biological Macromolecules]
Vijayakumar, M., Priya, K., Ilavenil, S., Janani, B., Vedarethinam, V., Ramesh, T., Arasu, M. V., Al-Dhabi, N. A., Kim, Y.-O., & Kim, H.-J. (2020). Shrimp shells extracted chitin in silver nanoparticle synthesis: Expanding its prophecy towards anticancer activity in human hepatocellular carcinoma HepG2 cells. International Journal of Biological Macromolecules. https://doi.org/10.1016/j.ijbiomac.2020.10.032 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Identification of a Dynamic Gene Regulatory Network Required for Pluripotency Factor-Induced Reprogramming of Mouse Fibroblasts and Hepatocytes

The authors investigated the early transcriptional events of cellular reprogramming triggered by the co‐expression of Oct4, Sox2, Klf4, and c‐Myc in mouse embryonic fibroblasts and mouse hepatocytes.
[EMBO Journal]
Papathanasiou, M., Tsiftsoglou, S. A., Polyzos, A. P., Papadopoulou, D., Valakos, D., Klagkou, E., Karagianni, P., Pliatska, M., Talianidis, I., Agelopoulos, M., & Thanos, D. (2020). Identification of a dynamic gene regulatory network required for pluripotency factor-induced reprogramming of mouse fibroblasts and hepatocytes. The EMBO Journal, n/a(n/a), e102236. https://doi.org/10.15252/embj.2019102236 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Prominin-1-Radixin Axis Controls Hepatic Gluconeogenesis by Regulating PKA Activity

Investigators analyzed the levels of mRNA transcripts in serum‐starved primary WT and KO mouse hepatocytes using RNA sequencing data, and found that cyclic AMP response element‐binding protein target genes were downregulated.
[EMBO Journal]
Lee, H., Yu, D.-M., Park, J. S., Lee, H., Kim, J.-S., Kim, H. L., Koo, S.-H., Lee, J.-S., Lee, S., & Ko, Y.-G. (2020). Prominin-1-Radixin axis controls hepatic gluconeogenesis by regulating PKA activity. EMBO Reports, n/a(n/a), e49416. https://doi.org/10.15252/embr.201949416 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Influence of NOS3 rs2070744 Genotypes on Hepatocellular Carcinoma Patients Treated with Lenvatinib

Researchers investigated whether or not nitric oxide synthase 3 (NOS3) rs2070744 genotypes could affect the response for lenvatinib treatment in patients with hepatocellular carcinoma.
[Scientific Reports]
Azuma, S., Uojima, H., Chuma, M., Shao, X., Hidaka, H., Nakazawa, T., Kondo, M., Numata, K., Iwabuchi, S., Kako, M., Maeda, S., Koizumi, W., & Atsuda, K. (2020). Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Scientific Reports, 10(1), 17054. https://doi.org/10.1038/s41598-020-73930-3 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Ribonuclease 7-Driven Activation of ROS1 Is a Potential Therapeutic Target in Hepatocellular Carcinoma

Oncogenic function of RNase7 was analyzed by cell proliferation, migration, invasion assays and xenograft mouse model. The anti-ROS1 inhibitor treatment efficacy was evaluated in hepatocellular carcinoma patient-derived xenograft and orthotopic models.
[Journal of Hepatology]
Liu, C., Zha, Z., Zhou, C., Chen, Y., Xia, W., Wang, Y.-N., Lee, H.-H., Yin, Y., Yan, M., Chang, C.-W., Chan, L.-C., Qiu, Y., Li, H., Li, C.-W., Hsu, J.-M., Hsu, J. L., Wang, S.-C., Ren, N., & Hung, M.-C. (2020). Ribonuclease 7-driven activation of ROS1 is a potential therapeutic target in hepatocellular carcinoma. Journal of Hepatology, 0(0). https://doi.org/10.1016/j.jhep.2020.09.030 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Virologists Who Discovered Hepatitis C Win Medicine Nobel

A trio of scientists who identified and characterized the virus responsible for many cases of hepatitis and liver disease- hepatitis C- are the recipients of the 2020 Nobel Prize in Physiology or Medicine.
[Nature News]
Press Release
Bookmark

No account yet? Register

0
Share

Hepatitis Is Still a Silent Killer in Africa and Elsewhere

New blood tests and drugs for this deadly disease have already saved millions of lives. But for millions more around the world, the celebration is bittersweet and the revolution in diagnosis and treatment remains a distant dream.
[STAT News]
Press Release
Bookmark

No account yet? Register

0
Share

Targeting Hepatocyte Growth Factor/C-Mesenchymal–Epithelial Transition Factor Axis in Hepatocellular Carcinoma: Rationale and Therapeutic Strategies

The authors collected the evidence of HGF/c‐Met as a tumor progression and prognostic marker, discussed the anti‐c‐Met therapy in vitro, summarized the outcome of c‐Met inhibitors in clinical trials, and identified potential impetus for future anti‐c‐Met treatments.
[Medicinal Research Reviews]
Yu, J., Chen, G. G., & Lai, P. B. S. (n.d.). Targeting hepatocyte growth factor/c-mesenchymal–epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies. Medicinal Research Reviews, n/a(n/a). https://doi.org/10.1002/med.21738 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Silencing p53 Inhibits Interleukin 10-Induced Activated Hepatic Stellate Cell Senescence and Fibrotic Degradation In Vivo

Scientists explored whether p53 played a crucial role in the senescence of activated hepatic stellate cells and degradation of collagen mediated by interleukin-10.
[Experimental Biology and Medicine]
Guo, Q., Chen, M., Chen, Q., Xiao, G., Chen, Z., Wang, X., & Huang, Y. (2020). Silencing p53 inhibits interleukin 10-induced activated hepatic stellate cell senescence and fibrotic degradation in vivo: Experimental Biology and Medicine. https://doi.org/10.1177/1535370220960391 Cite
Abstract
Bookmark

No account yet? Register

0
Share
Share